Efficient gene therapy-based method for the delivery of therapeutics to primate cortex
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Transduction of the primate cortex with adeno-associated virus (AAV)-based gene therapy vectors has been challenging, because of the large size of the cortex. We report that a single infusion of AAV2 vector into thalamus results in widespread expression of transgene in the cortex through transduction of widely dispersed thalamocortical projections. This finding has important implications for the treatment of certain genetic and neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kaplitt, M. G., Feigin, A., Tang, C., Fitzsimons, H. L., Mattis, P., Lawlor, P. A., Bland, R. J., Young, D., Strybing, K., Eidelberg, D., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60982-9 · Cited by 1,067
A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease
Tuszynski, M. H., Thal, L., Pay, M., Salmon, D. P., U, H. S., Bakay, R., Patel, P., Blesch, A., Vahlsing, H. L., Ho, G., et al. (2005) · Nature Medicine · doi:10.1038/nm1239 · Cited by 1,050 · cited 1×
“The prospect of being able to target widespread regions of the human cortex with AAV vectors that drive expression of secreted transgenes has obvious applications in Alzheimer’s disease (21, 22), lysosomal storage disorders (1, 23), and perhaps other serious disorders with a strong cortical manifestation.”
BackgroundRetrograde Viral Delivery of IGF-1 Prolongs Survival in a Mouse ALS Model
Kaspar, B. K., Lladó, J., Sherkat, N., Rothstein, J. D., & Gage, F. H. (2003) · Science · doi:10.1126/science.1086137 · Cited by 872 · cited 1×
“Anterograde (19) and retrograde (20) transport along axonal tracts is a consistently observed phenomenon in CED of AAV vectors.”
BackgroundResults from a phase I safety trial of hAADC gene therapy for Parkinson disease
Eberling, J. L., Jagust, W. J., Christine, C. W., Starr, P., Larson, P., Bankiewicz, K. S., & Aminoff, M. J. (2008) · Neurology · doi:10.1212/01.wnl.0000312381.29287.ff · Cited by 370 · cited 1×
“(7) and has been used clinically in gene therapy (AAV2-hAADC) for Parkinson’s disease (5).”
MethodSelf-citationCorticothalamic Projections from the Rat Primary Somatosensory Cortex
Killackey, H. P., & Sherman, S. M. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-19-07381.2003 · Cited by 131
Cited by
Therapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges
Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893
State-of-the-art gene-based therapies: the road ahead
Kay, M. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2971 · Cited by 666
The AAV Vector Toolkit: Poised at the Clinical Crossroads
Asokan, A., Schaffer, D. V., & Jude Samulski, R. (2012) · Molecular Therapy · doi:10.1038/mt.2011.287 · Cited by 465
Mehta, A. M., Sonabend, A. M., & Bruce, J. N. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0520-4 · Cited by 331
Gene therapy for neurological disorders: progress and prospects
Deverman, B. E., Ravina, B. M., Bankiewicz, K. S., Paul, S. M., & Sah, D. W. Y. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.110 · Cited by 306
Self-citation
Metadata
- Authors
- Kells, A. P., Hadaczek, P., Yin, D., Bringas, J., Varenika, V., Forsayeth, J., & Bankiewicz, K. S.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2009-02-17
- Volume
- 106
- Issue
- 7
- Pages
- 2407-2411
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2024421579
- Cited by
- 134
- References
- 5
- FWCI
- 7.13
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficient gene therapy-based method for the delivery of therapeutics to primate cortex. https://app.cochat.ai/papers/10.1073/pnas.0810682106
- The paper
- Kells, A. P., Hadaczek, P., Yin, D., Bringas, J., Varenika, V., Forsayeth, J., & Bankiewicz, K. S. (2009). Efficient gene therapy-based method for the delivery of therapeutics to primate cortex. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.0810682106
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.